Cargando…

Value-based genomics

Advancements in next-generation sequencing have greatly enhanced the development of biomarker-driven cancer therapies. The affordability and availability of next-generation sequencers have allowed for the commercialization of next-generation sequencing platforms that have found widespread use for cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Jun, Pan, Kathy, Fakih, Marwan, Pal, Sumanta, Salgia, Ravi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884665/ https://www.ncbi.nlm.nih.gov/pubmed/29644010 http://dx.doi.org/10.18632/oncotarget.24353

Ejemplares similares

Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience
por: Gong, Jun, et al.
Publicado: (2017)

Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
por: Salgia, Meghan, et al.
Publicado: (2017)

Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic
por: Salgia, Sabrina, et al.
Publicado: (2021)

Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Infectious complications of immune checkpoint inhibitors in solid organ malignancies
por: Ross, Justine Abella, et al.
Publicado: (2021)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Tivozanib in renal cell carcinoma: a new approach to previously treated disease
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions
por: Govindarajan, Ameish, et al.
Publicado: (2022)

Genomic mutation-driven metastatic breast cancer therapy: a single center experience
por: Yuan, Yuan, et al.
Publicado: (2017)

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
por: Gong, Jun, et al.
Publicado: (2018)

Renal Cell Carcinoma With Urinary Bladder Metastasis: A Case Report With Metachronous Genomic Analyses
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

1556. Infectious Disease Complications with Use of Checkpoint Inhibitors in Solid Organ Malignancies
por: Komoda, Kellie, et al.
Publicado: (2018)

Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations
por: Reckamp, Karen L, et al.
Publicado: (2020)

Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience
por: Yuan, Yuan, et al.
Publicado: (2017)

Recall of Genomic Testing Results Among Patients with Cancer
por: Wing, Sam E., et al.
Publicado: (2021)

Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2018)

Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma
por: Salgia, Ravi
Publicado: (2016)

Targeting KRAS(G12C)-Mutated Advanced Colorectal Cancer: Research and Clinical Developments
por: Ji, Jingran, et al.
Publicado: (2022)

Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Targeted therapies in the management of colorectal carcinoma: role of bevacizumab
por: Puthillath, Ajithkumar, et al.
Publicado: (2009)

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
por: Gong, Jun, et al.
Publicado: (2019)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

Heuristic value-based framework for lung cancer decision-making
por: Mambetsariev, Isa, et al.
Publicado: (2018)

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
por: Gong, Jun, et al.
Publicado: (2018)

Integrating Academic and Community Practices in the Management of Colorectal Cancer: The City of Hope Model
por: Karimi, Misagh, et al.
Publicado: (2020)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
por: Villaflor, Victoria M., et al.
Publicado: (2013)

Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies
por: Rajurkar, Swapnil, et al.
Publicado: (2020)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004)

Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California
por: Salgia, Nicholas J., et al.
Publicado: (2021)

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Stamp out lung cancer
por: Salgia, Ravi
Publicado: (2008)

Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors
por: Salgia, Ravi
Publicado: (2014)

Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2022)

Critical appraisal of cabazitaxel in the management of advanced prostate cancer
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients
por: Roosan, Moom R., et al.
Publicado: (2021)

FAK and paxillin, two potential targets in pancreatic cancer
por: Kanteti, Rajani, et al.
Publicado: (2016)

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021)

Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions
por: Pathak, Ranjan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cilm6ttgm8o218c8fig98voqie